{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:37:14Z","timestamp":1793126234207,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pharmthera.2024.108688","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:37:05Z","timestamp":1720215425000},"page":"108688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections"],"prefix":"10.1016","volume":"261","author":[{"given":"Emina K.","family":"Sher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"D\u017eidi\u0107-Krivi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma K.","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amila","family":"\u010celikovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merima","family":"Be\u0107a-Ze\u0107o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pinjic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4103\/UA.UA_104_19","article-title":"Management of urinary tract infection in women: A practical approach for everyday practice","volume":"11","author":"Abou Heidar","year":"2019","journal-title":"Urology Annals"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fmed.2019.00105","article-title":"Antimicrobial resistance in Nepal","volume":"6","author":"Acharya","year":"2019","journal-title":"Frontiers in Medicine"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijid.2018.12.017","article-title":"Antibiotic resistance in Bangladesh: A systematic review","volume":"80","author":"Ahmed","year":"2019","journal-title":"International Journal of Infectious Diseases"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108688_bb0020","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1128\/AAC.45.6.1751-1760.2001","article-title":"Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection","volume":"45","author":"Asahara","year":"2001","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0025","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10123-021-00184-y","article-title":"Threats of antibiotic resistance: An obliged reappraisal","volume":"24","author":"Baquero","year":"2021","journal-title":"International Microbiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00050-19","article-title":"Evolutionary pathways and trajectories in antibiotic resistance","volume":"34","author":"Baquero","year":"2021","journal-title":"Clinical Microbiology Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0035","article-title":"Overview of evidence of antimicrobial use and antimicrobial resistance in the food chain","volume":"9","author":"Bennani","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resistance Updates"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000499248","article-title":"A retrospective study of immunotherapy treatment with Uro-Vaxom (OM-89\u00ae) for prophylaxis of recurrent urinary tract infections","volume":"14","author":"Brodie","year":"2020","journal-title":"Curr Urol"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5588\/pha.21.0071","article-title":"Antibiotic resistance in patients with urinary tract infections in Pakistan","volume":"12","author":"Bullens","year":"2022","journal-title":"Public Health Action"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108688_bb0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","article-title":"Antibiotics in the clinical pipeline in October 2019","volume":"73","author":"Butler","year":"2020","journal-title":"Journal of Antibiotics (Tokyo)"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0060","first-page":"217","article-title":"Antibiotic resistance and Bacteria in urinary tract infections in pediatric patients","volume":"36","author":"Cag","year":"2021","journal-title":"Medeni Med J"},{"issue":"23","key":"10.1016\/j.pharmthera.2024.108688_bb0065","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.3390\/molecules25235593","article-title":"Promising roles of alternative medicine and plant-based nanotechnology as remedies for urinary tract infections","volume":"25","author":"Chandra","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114378","article-title":"Novel antimicrobial agents for combating antibiotic-resistant bacteria","volume":"187","author":"Chang","year":"2022","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0075","article-title":"Treatment of UTIs due to Klebsiella pneumoniae Carbapenemase-producers: How to use new antibiotic drugs? A Narrative Review","volume":"10","author":"Chapelle","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","article-title":"Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review","volume":"19","author":"Chegini","year":"2020","journal-title":"Annals of Clinical Microbiology and Antimicrobials"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108688_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087055","article-title":"Emerging non-antibiotic options targeting Uropathogenic mechanisms for recurrent uncomplicated urinary tract infection","volume":"24","author":"Chen","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108688_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11934-022-01094-w","article-title":"Non-antibiotic approaches to preventing pediatric UTIs: A role for D-mannose, cranberry, and probiotics?","volume":"23","author":"Ching","year":"2022","journal-title":"Current Urology Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108688_bb0095","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1128\/AAC.00390-16","article-title":"Efficacy of the novel antibiotic POL7001 in preclinical models of Pseudomonas aeruginosa pneumonia","volume":"60","author":"Cigana","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0100","first-page":"229","article-title":"Urinary tract infection in children: When to worry","volume":"37","author":"Clark","year":"2010","journal-title":"Urologic Clinics"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108688_bb0105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02385-20","article-title":"In Vitro and in vivo characterization of Tebipenem (TBP), an orally active Carbapenem, against biothreat pathogens","volume":"Vol. 65","author":"Clayton","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108688_bb0110","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s10096-018-3338-z","article-title":"Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. Coli and K. Pneumoniae: A retrospective observational case-series","volume":"37","author":"Cohen Stuart","year":"2018","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"23","key":"10.1016\/j.pharmthera.2024.108688_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237226","article-title":"Which antibiotic for urinary tract infections in pregnancy? A literature review of international guidelines","volume":"11","author":"Corrales","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108688_bb0120","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsinfecdis.8b00001","article-title":"Plazomicin retains antibiotic activity against Most aminoglycoside modifying enzymes","volume":"4","author":"Cox","year":"2018","journal-title":"ACS Infectious Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0125","first-page":"40","article-title":"Urinary tract infection in women","volume":"20","author":"Czajkowski","year":"2021","journal-title":"Menopause Review\/Przegl\u0105d Menopauzalny"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12010119","article-title":"In vivo role of two-component regulatory Systems in Models of urinary tract infections","volume":"12","author":"De Gaetano","year":"2023","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clinical Microbiology Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0140","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13312-022-2648-5","article-title":"Oral Faropenem sodium - implications for antimicrobial resistance and treatment effectiveness","volume":"59","author":"Dharmapalan","year":"2022","journal-title":"Indian Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010066","article-title":"FDA-approved oximes and their significance in medicinal chemistry","volume":"15","author":"Dhuguru","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0150","article-title":"Antibacterial potential of gold nanoparticles synthesized from leaf extract of Syzygium cumini against multidrug-resistant urinary tract pathogens","volume":"15","author":"Diksha","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0155","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s10096-019-03655-3","article-title":"Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period","volume":"38","author":"van Driel","year":"2019","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: A phase 3, Randomized Trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clinical Infectious Diseases"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108688_bb0165","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1021\/acs.jmedchem.0c00579","article-title":"Discovery of an orally available diazabicyclooctane inhibitor (ETX0282) of class a, C, and D serine \u03b2-lactamases","volume":"63","author":"Durand-Reville","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108688_bb0170","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1021\/acs.jmedchem.0c00579","article-title":"Discovery of an orally available Diazabicyclooctane inhibitor (ETX0282) of class A, C, and D serine \u03b2-lactamases","volume":"63","author":"Durand-R\u00e9ville","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108688_bb0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/03602532.2023.2186313","article-title":"Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs","volume":"55","author":"D\u017eidi\u0107-Krivi\u0107","year":"2023","journal-title":"Drug Metabolism Reviews"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108688_bb0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00618-19","article-title":"Safety, Pharmacokinetics, and food effect of Tebipenem Pivoxil Hydrobromide after single and multiple ascending Oral doses in healthy adult subjects","volume":"63","author":"Eckburg","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0185","doi-asserted-by":"crossref","first-page":"1180785","DOI":"10.3389\/fimmu.2023.1180785","article-title":"A suspension of inactivated bacteria used for vaccination against recurrent urinary tract infections increases the phagocytic activity of murine macrophages","volume":"14","author":"Eggers","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0190","first-page":"992","article-title":"Link between antibiotic persistence and antibiotic resistance in bacterial pathogens. Frontiers in cellular and infection","author":"Eisenreich","year":"2022","journal-title":"Microbiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108688_bb0195","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1080\/21645515.2020.1834807","article-title":"Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: Results from a first-in-human phase 1 study","volume":"17","author":"Eldridge","year":"2021","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00128072-200103020-00006","article-title":"Cefpodoxime proxetil: A review of its use in the management of bacterial infections in paediatric patients","volume":"3","author":"Fulton","year":"2001","journal-title":"Paediatric Drugs"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0205","doi-asserted-by":"crossref","first-page":"1048823","DOI":"10.3389\/fvets.2022.1048823","article-title":"Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs","volume":"9","author":"Gao","year":"2022","journal-title":"Frontiers in Veterinary Science"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0210","article-title":"Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: Population based cohort study","volume":"364","author":"Gharbi","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02225-19","article-title":"Antibiotic resistance and epigenetics: More to it than meets the eye","volume":"64","author":"Ghosh","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108688_bb0220","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/biology11121711","article-title":"A review of Pseudomonas aeruginosa Metallophores: Pyoverdine, Pyochelin and Pseudopaline","volume":"11","author":"Ghssein","year":"2022","journal-title":"Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108688_bb0225","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ijantimicag.2019.01.010","article-title":"Efficacy of ceftolozane\/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model","volume":"53","author":"G\u00f3mez-Junyent","year":"2019","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108688_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25153523","article-title":"Cranberry polyphenols and prevention against urinary tract infections: Relevant considerations","volume":"25","author":"Gonz\u00e1lez de Llano","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0235","first-page":"47","article-title":"Correlation between biofilm formation and antibiotic resistance in Pseudomonas aeruginosa: A meta-analysis","volume":"28","author":"Hadadi-Fishani","year":"2020","journal-title":"Le Infezioni in Medicina"},{"issue":"20","key":"10.1016\/j.pharmthera.2024.108688_bb0240","first-page":"1730","article-title":"Updated Meta-analysis: Cranberry products reduced UTI risk","volume":"329","author":"Harris","year":"2023","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108688_bb0245","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202051034","article-title":"Antibiotic resistance and persistence\u2014Implications for human health and treatment perspectives","volume":"21","author":"Huemer","year":"2020","journal-title":"EMBO Reports"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-021-00481-4","article-title":"Differences of virulence factors, and antimicrobial susceptibility according to phylogenetic group in uropathogenic Escherichia coli strains isolated from Korean patients","volume":"20","author":"Hyun","year":"2021","journal-title":"Annals of Clinical Microbiology and Antimicrobials"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2024.108688_bb0255","article-title":"Bioinspired engineered nickel nanoparticles with multifunctional attributes for reproductive toxicity","volume":"311","author":"Iftikhar","year":"2023","journal-title":"Chemosphere"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108688_bb0260","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14787210.2018.1496821","article-title":"Tebipenem, the first oral carbapenem antibiotic","volume":"16","author":"Jain","year":"2018","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0265","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/fmb-2019-0333","article-title":"Global priority pathogens: Virulence, antimicrobial resistance and prospective treatment options","volume":"15","author":"JC, M.C","year":"2020","journal-title":"Future Microbiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108688_bb0270","article-title":"IL-1\u03b2 in correlation to the common diabetic complications","volume":"5","author":"Karahmet","year":"2021","journal-title":"Acta Scientific Medical Sciences (ISSN: 2582\u20130931)"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0275","doi-asserted-by":"crossref","DOI":"10.17392\/1279-21","article-title":"Clinical use of an analysis of oxidative stress and IL-6 as the promoters of diabetic polyneuropathy","volume":"18","author":"Karahmet","year":"2021","journal-title":"Medicinski Glasnik"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0280","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01832-18","article-title":"In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2022.136885","article-title":"Functional bioinspired nanocomposites for anticancer activity with generation of reactive oxygen species","volume":"310","author":"Khalid","year":"2023","journal-title":"Chemosphere"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0290","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41579-020-0324-0","article-title":"Urinary tract infections: Microbial pathogenesis, host\u2013pathogen interactions and new treatment strategies","volume":"18","author":"Klein","year":"2020","journal-title":"Nature Reviews Microbiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108688_bb0295","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14787210.2019.1664287","article-title":"Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: A controlled pilot study","volume":"17","author":"Koradia","year":"2019","journal-title":"Expert Review of Anti-Infective Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-3785-x","article-title":"Uncomplicated urinary tract infections in Swedish primary care; etiology, resistance and treatment","volume":"19","author":"Kornf\u00e4lt Isberg","year":"2019","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0305","doi-asserted-by":"crossref","first-page":"403","DOI":"10.33073\/pjm-2019-048","article-title":"Antibiotic resistance among Uropathogenic Escherichia coli","volume":"68","author":"Kot","year":"2019","journal-title":"Polish Journal of Microbiology"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bju.16247","article-title":"Evaluation of MV140 in preventing recurrent UTIs - a multi-Centre double-blinded RCT protocol","volume":"133","author":"Kovacic","year":"2023","journal-title":"BJU International"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.mib.2022.102150","article-title":"Antibiotic resistance in the commensal human gut microbiota","volume":"68","author":"Lamberte","year":"2022","journal-title":"Current Opinion in Microbiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00084-22","article-title":"Emergence of high-level Cefiderocol resistance in Carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in patients with hematologic malignancies in China","volume":"10","author":"Lan","year":"2022","journal-title":"Microbiology Spectrum"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108688_bb0325","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/femsre\/fuz014","article-title":"Antibiotic resistance breakers: Current approaches and future directions","volume":"43","author":"Laws","year":"2019","journal-title":"FEMS Microbiology Reviews"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108688_bb0330","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40261-020-00955-x","article-title":"Cefiderocol, a new Siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: Preclinical and clinical pharmacokinetics, pharmacodynamics, Efficacy and Safety","volume":"40","author":"Lee","year":"2020","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0335","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221109023","article-title":"Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases","volume":"14","author":"Loloi","year":"2022","journal-title":"Therapeutic Advances in Urology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0340","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.13330","article-title":"The glycobiology of uropathogenic E. Coli infection: The sweet and bitter role of sugars in urinary tract immunity","volume":"164","author":"Lupo","year":"2021","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11332","article-title":"Synthesis, characterization, molecular docking and biological evaluation of Schiff Base derivatives of cefpodoxime","volume":"8","author":"Mahmood","year":"2022","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108688_bb0350","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00603-19","article-title":"Pharmacodynamics of Tebipenem: New options for Oral treatment of multidrug-resistant gram-negative infections","volume":"63","author":"McEntee","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108688_bb0355","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acsinfecdis.0c00020","article-title":"In vitro characterization of ETX1317, a broad-Spectrum \u03b2-lactamase inhibitor that restores and enhances \u03b2-lactam activity against multi-drug-resistant Enterobacteriales, Including Carbapenem-Resistant Strains","volume":"6","author":"Miller","year":"2020","journal-title":"ACS Infectious Diseases"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108688_bb0360","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1128\/AAC.37.7.1547","article-title":"In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic","volume":"37","author":"Minamimura","year":"1993","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0365","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s12879-023-08641-x","article-title":"Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in Morogoro, Tanzania: A cross-sectional study","volume":"23","author":"Mlugu","year":"2023","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5507\/bp.2018.070","article-title":"Molecular mechanisms of polymyxin resistance and detection of mcr genes","volume":"163","author":"Mlynarcik","year":"2019","journal-title":"Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0375","first-page":"10","article-title":"Pattern of antibacterial resistance in urinary tract infections: A systematic review and meta-analysis. International journal of","author":"Mortazavi-Tabatabaei","year":"2019","journal-title":"Preventive Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2024.108688_bb0380","article-title":"LB-3. Oral Tebipenem Pivoxil Hydrobromide is non-inferior to IV Ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) \u2013 Results from the pivotal ADAPT-PO study","volume":"7","author":"Muir","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.691210","article-title":"Recurrent urinary tract infection: A mystery in search of better model systems","volume":"11","author":"Murray","year":"2021","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0390","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s11255-021-02987-4","article-title":"Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: A comparative single-Centre study","volume":"53","author":"Nestler","year":"2021","journal-title":"International Urology and Nephrology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0395","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00218-20","article-title":"Advances in understanding the human urinary microbiome and its potential role in urinary tract infection","volume":"11","author":"Neugent","year":"2020","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0400","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001458","article-title":"Invasion and diversity in Pseudomonas aeruginosa urinary tract infections","volume":"71","author":"Newman","year":"2022","journal-title":"Journal of Medical Microbiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0405","first-page":"25","article-title":"MV140 sublingual vaccine reduces recurrent urinary tract infection in women: Results from the first north American clinical experience study","volume":"18","author":"Nickel","year":"2024","journal-title":"Canadian Urological Association Journal"},{"issue":"Pt 4","key":"10.1016\/j.pharmthera.2024.108688_bb0410","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1107\/S2056989022002110","article-title":"Crystal structures of anhydrous and hydrated ceftibuten","volume":"78","author":"Nisbet","year":"2022","journal-title":"Acta Crystallogr E Crystallogr Commun"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0415","article-title":"Drug and vaccine development for the treatment and prevention of urinary tract infections","volume":"4","author":"O'Brien","year":"2016","journal-title":"Microbiology Spectrum"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108688_bb0420","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1021\/acsinfecdis.0c00019","article-title":"Pharmacokinetic\/Pharmacodynamic determination and preclinical pharmacokinetics of the \u03b2-lactamase inhibitor ETX1317 and its orally available prodrug ETX0282","volume":"6","author":"O'Donnell","year":"2020","journal-title":"ACS Infectious Diseases"},{"issue":"19","key":"10.1016\/j.pharmthera.2024.108688_bb0425","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.3390\/molecules24193430","article-title":"Comparison of antibiotic resistance mechanisms in antibiotic-producing and pathogenic bacteria","volume":"24","author":"Ogawara","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0430","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11934-007-0080-y","article-title":"Viral lower urinary tract infections","volume":"8","author":"Paduch","year":"2007","journal-title":"Current Urology Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0435","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnology Advances"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0440","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1139\/w06-065","article-title":"Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge","volume":"52","author":"Poggio","year":"2006","journal-title":"Canadian Journal of Microbiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0445","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euf.2019.11.002","article-title":"Role of vaccines for recurrent urinary tract infections: A systematic review","volume":"6","author":"Prattley","year":"2020","journal-title":"European Urology Focus"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0450","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","article-title":"Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/nano11020546","article-title":"Nanomaterials for the diagnosis and treatment of urinary tract infections","volume":"11","author":"Qindeel","year":"2021","journal-title":"Nanomaterials (Basel)"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-018-0411-4","article-title":"Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains","volume":"7","author":"Raeispour","year":"2018","journal-title":"Antimicrobial Resistance & Infection Control"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0465","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cbpa.2011.02.015","article-title":"Protein epitope mimetics as anti-infectives","volume":"15","author":"Robinson","year":"2011","journal-title":"Current Opinion in Chemical Biology"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0470","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-4-13","article-title":"Urinary tract infections in the elderly: A review of disease characteristics and current treatment options","volume":"9","author":"Rodriguez-Ma\u00f1as","year":"2020","journal-title":"Drugs in Context"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108688_bb0475","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00590-22","article-title":"Plasma and intrapulmonary concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to healthy adult subjects","volume":"66","author":"Rodvold","year":"2022","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"83","key":"10.1016\/j.pharmthera.2024.108688_bb0480","doi-asserted-by":"crossref","first-page":"eabn4332","DOI":"10.1126\/sciimmunol.abn4332","article-title":"Tissue-resident memory T cells mediate mucosal immunity to recurrent urinary tract infection","volume":"8","author":"Rousseau","year":"2023","journal-title":"Science Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/acsami.5b09730","article-title":"Quasi-instantaneous bacterial inactivation on cu-ag Nanoparticulate 3D catheters in the dark and under light: Mechanism and dynamics","volume":"8","author":"Rtimi","year":"2016","journal-title":"ACS Applied Materials & Interfaces"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108688_bb0490","first-page":"ofad058","volume":"10","author":"Sader","year":"2023","journal-title":"Infectious Diseases"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0495","first-page":"386","article-title":"Antibiotic resistance in childhood urinary tract infections: A single-center experience","volume":"55","author":"Samanc\u0131","year":"2020","journal-title":"Turkish Archives of Pediatrics\/T\u00fcrk Pediatri Ar\u015fivi"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.656496","article-title":"Nanoparticles as potential novel therapies for urinary tract infections","volume":"11","author":"S\u00e1nchez","year":"2021","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0505","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4103\/jehp.jehp_557_21","article-title":"Antibiotics at the crossroads - do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance?","volume":"10","author":"Sannathimmappa","year":"2021","journal-title":"Journal of Education Health Promotion"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108688_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158080","article-title":"Coming from the wild: Multidrug resistant opportunistic pathogens presenting a primary, not human-linked, environmental habitat","volume":"22","author":"Sanz-Garc\u00eda","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0515","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acsinfecdis.0c00656","article-title":"Interactions of the Diazabicyclooctane serine \u03b2-lactamase inhibitor ETX1317 with target enzymes","volume":"7","author":"Shapiro","year":"2021","journal-title":"ACS Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12887-019-1410-1","article-title":"Clinical, etiological and antimicrobial susceptibility profile of pediatric urinary tract infections in a tertiary care hospital of Nepal","volume":"19","author":"Shrestha","year":"2019","journal-title":"BMC Pediatrics"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108688_bb0525","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41585-018-0106-x","article-title":"Nonantibiotic prevention and management of recurrent urinary tract infection","volume":"15","author":"Sihra","year":"2018","journal-title":"Nature Reviews Urology"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108688_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/ma14154125","article-title":"Ciprofloxacin-releasing ROS-sensitive nanoparticles composed of poly(ethylene glycol)\/poly(D,L-lactide-co-glycolide) for Antibacterial Treatment","volume":"14","author":"Song","year":"2021","journal-title":"Materials (Basel)"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108688_bb0535","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1093\/jac\/dkaa183","article-title":"Oral cephalosporin and \u03b2-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections","volume":"75","author":"Stewart","year":"2020","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0540","first-page":"473","article-title":"Treatment of fungal urinary tract infection","volume":"42","author":"Thomas","year":"2015","journal-title":"Urologic Clinics"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0545","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.2147\/IDR.S337611","article-title":"Emerging Carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: A review","volume":"14","author":"Tilahun","year":"2021","journal-title":"Infection and Drug Resistance"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108688_bb0550","doi-asserted-by":"crossref","first-page":"10155","DOI":"10.1021\/acs.jmedchem.1c00437","article-title":"Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An orally bioavailable \u03b2-lactamase inhibitor for Enterobacterales expressing ambler class A, C, and D enzymes","volume":"64","author":"Trout","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108688_bb0555","doi-asserted-by":"crossref","first-page":"10155","DOI":"10.1021\/acs.jmedchem.1c00437","article-title":"Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An orally bioavailable \u03b2-lactamase inhibitor for Enterobacterales expressing ambler class A, C, and D enzymes","volume":"64","author":"Trout","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0560","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jgar.2019.06.016","article-title":"Antibiotic treatment and antimicrobial resistance in children with urinary tract infections","volume":"20","author":"Vazouras","year":"2020","journal-title":"Journal of Global Antimicrobial Resistance"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108688_bb0565","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s40121-021-00509-4","article-title":"Oral antibiotics in clinical development for community-acquired urinary tract infections","volume":"10","author":"Veeraraghavan","year":"2021","journal-title":"Infectious Diseases and Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108688_bb0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40121-020-00374-7","article-title":"Orally administered amoxicillin\/Clavulanate: Current role in outpatient therapy","volume":"10","author":"Veeraraghavan","year":"2021","journal-title":"Infectious Disease and Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108688_bb0575","article-title":"Current and emerging treatment options for multidrug resistant Escherichia coli Urosepsis: A review","volume":"11","author":"Walker","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0580","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00404-019-05256-z","article-title":"Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance\u2014Non-antibiotic approaches: A systemic review","volume":"300","author":"Wawrysiuk","year":"2019","journal-title":"Archives of Gynecology and Obstetrics"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108688_bb0585","first-page":"Cd001321","article-title":"Cranberries for preventing urinary tract infections","volume":"11","author":"Williams","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108688_bb0590","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A Siderophore cephalosporin with activity against Carbapenem-resistant and multidrug-resistant gram-negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108688_bb0595","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-022-01688-1","article-title":"Sulopenem: An intravenous and Oral Penem for the treatment of urinary tract infections due to multidrug-resistant Bacteria","volume":"82","author":"Zhanel","year":"2022","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108688_bb0600","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2024.108688_bb0605","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fcimb.2019.00128","article-title":"Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics-a novel way to combat antibiotic resistance?","volume":"9","author":"Zharkova","year":"2019","journal-title":"Frontiers in Cellular and Infection Microbiology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T05:25:02Z","timestamp":1722662702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":121,"alternative-id":["S0163725824001086"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108688","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108688"}}